This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The future of lifesciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, according to new research from Gartner. From CRM to CXM.
If there was an AI solution in the LifeSciences field, able to represent a real opportunity in terms of Customer Engagement and Digital Transformation, and if some of the most important players in the industry already had it, would you like to have the opportunity to listen to them? . . ” . .
The annual event assembled nearly 1,000 attendees from over 40+ countries across the healthcare ecosystem to learn, network and explore industry challenges, strategic trends and solutions in lifesciences and healthcare.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. The global wearable medical devices market size was valued at $73.77
Jupiter Neurosciences, a clinical-stage pharmacompany specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00
If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the lifesciences. Here is a look at some lifescience trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.
Family businesses across industries including the lifesciences sector contribute significantly to the global economy – they represent about half of the world gross domestic product and global employment. In the lifesciences sector, the overall goal is to develop and commercialise innovative pharmaceutical solutions to improve health.
In an April survey conducted by Reuters and Omnipresence, 1,363 senior professionals mostly working in pharma (82.8%) in the EMEA region (73%) and biotech, medtech/device or consumer health companies reported on how lifesciences organisations were adapting to the ‘new normal’.
The amount of money required to gain approval of a new drug has been hotly debated, but it also costs a hell of a lot of money to launch a drug in today’s market. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 Only about $2.2
ODAIA, a lifesciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by lifescience brands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.
As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. This is reinforced by web-focused marketing strategies that give them a highly-targeted approach when it comes to marketing execution.”. Be more agile .
Ehab graduated from Harvard Business school’s Executive General Management Programme in 2009 and holds a bachelor’s degree in Pharmaceutical Sciences. The post The largest pharmacompany in Europe calls for interoperability appeared first on. About the author .
For the past year, lifesciencecompanies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. India and China have seen the emergence of strong, local pharmacompanies. With India and China having populations of 1.3
In this episode, Ayesha talked about some of the trends to look out for in the lifesciences in 2023. Also hear about the issue of drug shortages and how pharmacompanies hope to tackle it in 2023. Read the full article here: 4 LifeSciences Trends for 2023.
Among these, mergers and acquisitions (M&As) have played a pivotal role in reshaping the industry landscape, enabling companies to bolster their portfolios, enhance R&D capabilities and expand their global market reach. Actavis Acquisition of Allergan Deal value : $70.5
Before the Covid-19 pandemic, government-led investment and engagement in lifesciences was relatively restricted worldwide, with the industry mostly funded via private investment. Many new therapeutics are needed to treat the broad range of bacterial infections, and bringing new antibiotics to market is both difficult and expensive.
Organisations are missing out on the ability to harness their data to energise precision marketing and transform commercial performance. The pharma industry is adjusting to massive upheaval from the pandemic and markets are emerging from its grip reshaped and alive with competition. Deeper Insights. Single View of HCPs.
Data is transforming lifesciences, but many organisations are not using its full potential. Lifesciences and the pharmaceutical industry are awash with data. Capturing market share. The combination of health and data, he passionately believes, will transform lifesciences. billion in 2021 to $9.23
Ontario, Canada’s largest province by population, is stepping up its commitment to the lifesciences sector with an investment of $40 million. The $40 million will come from the Venture Ontario Fund, which is dedicated to helping Ontario lifesciencescompanies and biomanufacturers innovate, grow and compete in global markets.
In 2023, there were significant advancements and notable trends in the lifesciences. Xtalks compiled a list of its top lifescience news and trends of 2023, which provided readers with the latest developments, information and expert insights across lifescience industries, including pharma, biotech and medical device.
However, some of the key pharmacompanies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. Multiple Sclerosis (MS).
Full lifecycle recruitment can help lifescience and pharmacompanies find the best talent to fill job postings. Recruiters, HR leaders and leaders in the lifesciences and pharma who manage people can benefit from using full lifecycle recruiting to enhance a lifesciences organization’s hiring process.
At present, there are several nonsurgical and surgical options in the Fecal Incontinence market. Conservative treatment approaches in the FI theraoy market include bulking agents and biofeedback. However, Biofeedback is the gold standard of the non-operative strategies in the FI therapeutics market.
Pharmacompanies have improved how they engage with healthcare providers as a result of COVID-19, according to a new survey of HCPs. This has resulted in pharmacompanies being more relevant and providing more value in closing the care gap, the report says.
Moreover, AI has the power to fuel a broad reach, extending out into local, national and international markets to harness data from user profiles worldwide. By leveraging AI technology, organizations can cut the time spent on advertising on job boards, social media and manually going through resumes and profiles online.
The lifesciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the lifesciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
Eversana’s suite of commercialisation tools for pharmacompanies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. pic.twitter.com/MUKcXaganu. — Limitless Minds (@Thinkbig_gofar) July 25, 2019.
PBMs, insurers, pharmacompanies, and hospitals don’t want to give up their profits even if it’s better for the general population. The company has hired former senior health regulators to help it navigate America’s healthcare bureaucracy. .
N o one industry is ever quite like another, but there are some valuable lessons for pharmamarketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. Within this, the progressive pharmacompanies are utilising modular content to increase brand standards.
Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.
The heart and vascular medication market continues to be a critical focus area for pharmacompanies, with billions of dollars in sales generated annually. However, challenges such as patent expirations, generic competition and pricing pressures continue to shape the market landscape. In 2023, Pfizer generated $6.75
If pharmacompanies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric teams, according to one digital transformation leader. Pharmacompanies really need to become patient, but also healthcare professional, centric.
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. November saw the launch of a new private equity team in lifesciences at J.P. Morgan Asset Management, dubbed LifeSciences Private Capital. New CEO joins UBC.
The annual peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma highlights companies that have demonstrated innovative solutions, technologies, and services and have the potential to make the greatest impact for biotech and pharmacompanies.?. 2020 Accolades. About Fierce Innovation Awards.
At Fishawack Health, we are always seeking opportunities to enhance our capabilities and help our lifescience clients navigate the new, dynamically changing healthcare environment. Meet closerlook. The COVID-19 pandemic has highlighted the necessity of digital communication and the opportunities an omnichannel approach brings.
Since the onset of the Covid-19 pandemic, lifesciencecompanies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). For the most part, lifesciencecompanies have a relatively good knowledge of what their audiences want and need from them.
Pharmacompanies are producing and distributing more digital content than ever due to the pandemic, meaning the content presented needs to stand out in the crowded digital space to garner attention. Content metrics is the collection of data related to an industry or a company’s content. New content does not need to be rewritten.
Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharmacompanies to maintain up-to-date customer data. Rather than simply surviving, the lifesciences industry needs to respond proactively. About Veeva Systems.
The global pharmaceutical market has been expanding at an unprecedented pace. According to Statista , in 2023, the market was estimated to be worth about $1.6 The top ten pharmacompanies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 billion last year, up 4.2
86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating a greater volume of content now, compared to six months ago. To assist executives in lifesciences with scaling marketing assets in a virtual world Veeva has published a new eBook, Powering Omnichannel Strategies with Modular Content.
A new survey highlights the importance of customer reference data to digital transformation and analyses ways pharmacompanies can improve the quality of their datasets. More pharmacompanies are moving in this direction, and 78% of respondents said they are undertaking, or planning, a customer data enhancement initiative.
Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from lifesciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a lifesciences future very much immersed in speciality medicine?
While implemented to improve transparency and market competition, this new legislation has caused considerable upheaval for clinical trial providers. But if they’re doing that internally, they may have a bias, either because of a lifesciences background or involvement in the clinical trial itself.
Market pressures. Veeva highlights in the whitepaper that marketing and sales functions need to work closely together to deliver the right messages aligned with doctors’ real needs. Pharma needs to listen to what doctors are saying,” Noel says. Companies need to experiment with new ways of working and not be afraid to fail.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content